<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04730648</url>
  </required_header>
  <id_info>
    <org_study_id>Litangzhiming</org_study_id>
    <nct_id>NCT04730648</nct_id>
  </id_info>
  <brief_title>Acute Myocardial Infarction and Unstable Angina Patients With PCSK9 Inhibitor Usage Study</brief_title>
  <official_title>Acute Myocardial Infarction and Unstable Angina Patients With PCSK9 Inhibitor Usage Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute coronary syndrome (ACS) is a lethal disease, reduced low-density lipoprotein (LDL)&#xD;
      cholesterol due to inhibition of proprotein convertase subtilisin/kexin 9 (PCSK9) reduces&#xD;
      cardiovascular events and improve cardiovascular prognosis. we assuming that PCSK9 inhibitor&#xD;
      could bring metabolic change in serum, in order to investigate the metabolic modification, we&#xD;
      conduct this clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2021</start_date>
  <completion_date type="Anticipated">April 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 23, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cardiovascular prognosis</measure>
    <time_frame>52 weeks</time_frame>
    <description>composite outcome of time to first occurrence of cardiovascular death, myocardial infarction, unstable angina and heart failure.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Lipid Metabolism</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>pcsk9 inhibitor group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with severe coronary stenosis diagnosed ACS. The baseline blood and urine would be collected, thereafter, the PCSK9 inhibitor would be injected. 64-72 hours after, the blood and urine sample collection would be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with comparable age, sex ratio, and BMI, but coronary arteries are relatively normal evaluated by coronary angiography. their blood and urine would be collected as the control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PCSK9 inhibitor</intervention_name>
    <description>For newly diagnosed ACS patients with diabetes, multivessel occlusion, or recurrent ACS attack, who are willing to accept PCSK9 inhibitor injection.</description>
    <arm_group_label>pcsk9 inhibitor group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  New diagnosis ACS patient by serum biomarker and coronary arteriography.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe renal dysfunction acute or chronic bacterial and viral infections sleep apnea&#xD;
             cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tangzhiming Li, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Shenzhen People's Hospital, Shenzhen 518020, Guangdong, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tangzhiming Li, PhD.</last_name>
    <phone>+86 18588269277</phone>
    <email>litangzhiming@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shaohong Dong, PhD.</last_name>
    <phone>+86 13509633742</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tangzhiming Li</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tangzhiming Li, PhD.</last_name>
      <phone>+86 18588269277</phone>
      <email>litangzhiming@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Shaohong Dong, PhD.</last_name>
      <phone>+86 13509633742</phone>
      <email>119538892@qq.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 26, 2020</study_first_submitted>
  <study_first_submitted_qc>January 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2021</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shenzhen People's Hospital</investigator_affiliation>
    <investigator_full_name>Ying Li</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

